Corporate Comment


References 1 Emmert-Buck, MR. Translational research: From biological discovery to public benefit (or not). Advances in Biology. 2014;2014. 2 Bliss, M. The discovery of insulin: Twenty-fifth anniversary edition. University Of Chicago Press; 2007. 3 Cooper, T, Ainsberg, A. Breakthrough: Elizabeth hughes, the discovery of insulin, and the making of a medical miracle. Publisher: St. Martin’s Griffin; 2011. 4 Singh, NN, Howell, MD, Androphy, EJ, Singh, RN. How the discovery of iss-n1 led to the first medical therapy for spinal muscular atrophy. Gene therapy. 2017. 5 Awano, T, Kim, JK, Monani, UR. Spinal muscular atrophy: Journeying from bench to bedside. Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics. 2014;11:786-795. 6 Pammolli, F, Magazzini, L, Riccaboni, M. The productivity crisis in pharmaceutical r&d. Nature reviews. Drug discovery. 2011;10:428-438. 7 DiMasi, JA, Grabowski, HG, Hansen, RW. The cost of drug development. The New England journal of medicine. 2015;372:1972. 8Waring, MJ, Arrowsmith, J, Leach, AR, Leeson, PD, Mandrell, S, Owen, RM et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nature reviews. Drug discovery. 2015;14:475-486. 9 BIO. Clinical development success rates 2006- 2015. 2016. 10 Benatar, M. Lost in translation: Treatment trials in the sod1 mouse and in human als. Neurobiology of disease. 2007;26:1-13. 11 Shineman, DW, Basi, GS, Bizon, JL, Colton, CA, Greenberg, BD, Hollister, BA et al. Accelerating drug discovery for Alzheimer’s Disease: Best practices for preclinical animal studies. Alzheimer’s research & therapy. 2011;3:28. 12 van der Worp, HB, Howells, DW, Sena, ES, Porritt, MJ, Rewell, S, O’Collins, V et al. Can animal models of disease reliably inform human studies? PLoS medicine. 2010;7:e1000245. 13 Jucker, M. The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nature medicine. 2010;16:1210-1214. 14 Karran, E, Hardy, J. A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for alzheimer disease. Annals of neurology. 2014;76:185-205. 15 Herter-Sprie, GS, Kung, AL, Wong, KK. New cast for a new era: Preclinical cancer drug development revisited. The Journal of clinical investigation. 2013;123:3639-3645. 16 Scannell, JW, Blanckley, A, Boldon, H, Warrington, B. Diagnosing the decline in pharmaceutical r&d efficiency. Nature reviews. Drug discovery. 2012;11:191-200. 17 Mak, IW, Evaniew, N, Ghert, M. Lost in translation: Animal models and clinical trials in cancer treatment. American journal of translational research. 2014;6:114-118. 18 Moore, JD. The impact of crispr-cas9 on target identification and validation. Drug discovery today. 2015;20:450-457. 19 Dow, LE. Modeling disease in vivo with crispr/cas9. Trends in molecular medicine. 2015;21:609-621.


Drug Discovery World Fall 2017


20 Fellmann, C, Gowen, BG, Lin, PC, Doudna, JA, Corn, JE. Cornerstones of crispr-cas in drug discovery and therapy. Nature reviews. Drug discovery. 2017;16:89-100. 21 Nestler, EJ, Hyman, SE. Animal models of neuropsychiatric disorders. Nature neuroscience. 2010;13:1161-1169. 22 McGonigle, P, Ruggeri, B. Animal models of human disease: Challenges in enabling translation. Biochemical pharmacology. 2014;87:162-171. 23 Laurijssens, B, Aujard, F, Rahman, A. Animal models of Alzheimer’s Disease and drug development. Drug discovery today. Technologies. 2013;10:e319-327. 24 Onos, KD, Sukoff Rizzo, SJ, Howell, GR, Sasner, M. Toward more predictive genetic mouse models of alzheimer's disease. Brain research bulletin. 2016;122:1-11. 25 Burns, TC, Li, MD, Mehta, S, Awad, AJ, Morgan, AA. Mouse models rarely mimic the transcriptome of human neurodegenerative diseases: A systematic bioinformatics-based critique of preclinical models. European journal of pharmacology. 2015;759: 101-117. 26 Cavanaugh, SE, Pippin, JJ, Barnard, ND. Animal models of Alzheimer’s Disease: Historical pitfalls and a path forward. Altex. 2014;31:279-302. 27 Seok, J, Warren, HS, Cuenca, AG, Mindrinos, MN, Baker, HV, Xu, W et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proceedings of the National Academy of Sciences of the United States of America. 2013;110:3507-3512. 28Takao, K, Miyakawa, T. Genomic responses in mouse models greatly mimic human inflammatory diseases. Proceedings of the National Academy of Sciences of the United States of America. 2015;112:1167-1172. 29Weidner, C, Steinfath, M, Opitz, E, Oelgeschlager, M, Schonfelder, G. Defining the optimal animal model for translational research using gene set enrichment analysis. EMBO molecular medicine. 2016;8:831-838. 30 Galatro, TF, Vainchtein, ID, Brouwer, N, Boddeke, EW, Eggen, BJ. Isolation of microglia and immune infiltrates from mouse and primate central nervous system. Methods in molecular biology. 2017;1559:333-342. 31 Feldmann, M. Development of anti-tnf therapy for rheumatoid arthritis. Nature reviews. Immunology. 2002;2:364-371. 32 Klinghammer, K, Walther, W, Hoffmann, J. Choosing wisely – preclinical test models in the era of precision medicine. Cancer treatment reviews. 2017;55:36-45. 33 Koch, LG, Pollott, GE, Britton, SL. Selectively bred rat model system for low and high response to exercise training. Physiological genomics. 2013;45:606-614. 34 Asgharpour, A, Cazanave, SC, Pacana, T, Seneshaw, M, Vincent, R, Banini, BA et al. A diet- induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. Journal of hepatology. 2016;65:579-588. 35 Morris, EM, McCoin, CS, Allen, JA, Gastecki, ML, Koch, LG, Britton, SL et al. Aerobic capacity mediates susceptibility for the transition from steatosis to steatohepatitis. The Journal of physiology. 2017;595:4909-4926.


36 Morgan, AJ, Parker, S. Translational mini-review series on vaccines: The edward jenner museum and the history of vaccination. Clinical and experimental immunology. 2007;147:389-394. 37 Manolio, TA, Fowler, DM, Starita, LM, Haendel, MA, MacArthur, DG, Biesecker, LG et al. Bedside back to bench: Building bridges between basic and clinical genomic research. Cell. 2017;169:6-12. 38 Mitchell, KJ, Huang, ZJ, Moghaddam, B, Sawa, A. Following the genes: A framework for animal modeling of psychiatric disorders. BMC biology. 2011;9:76. 39 da Silva, Xavier G, Bellomo, EA, McGinty, JA, French, PM, Rutter, GA. Animal models of gwas- identified type 2 diabetes genes. Journal of diabetes research. 2013;2013:906590. 40 Shen, T, Lee, A, Shen, C, Lin, CJ. The long tail and rare disease research: The impact of next- generation sequencing for rare mendelian disorders. Genetics research. 2015;97:e15. 41 Miller, JN, Kovacs, AD, Pearce, DA. The novel cln1(r151x) mouse model of infantile neuronal ceroid lipofuscinosis (incl) for testing nonsense suppression therapy. Human molecular genetics. 2015;24:185-196. 42 Kwa, M, Makris, A, Esteva, FJ. Clinical utility of gene-expression signatures in early stage breast cancer. Nature reviews. Clinical oncology. 2017. 43 Lee, JS. Exploring cancer genomic data from the cancer genome atlas project. BMB reports. 2016;49:607-611. 44 Hendrickx, W, Simeone, I, Anjum, S, Mokrab, Y, Bertucci, F, Finetti, P et al. Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. Oncoimmunology. 2017;6:e1253654. 45 Shen, T, Pajaro-Van de Stadt, SH, Yeat, NC, Lin, JC. Clinical applications of next generation sequencing in cancer: From panels, to exomes, to genomes. Frontiers in genetics. 2015;6:215. 46 Castiello, L, Sabatino, M, Ren J, Terabe, M, Khuu, H, Wood, LV et al. Expression of cd14, il10, and tolerogenic signature in dendritic cells inversely correlate with clinical and immunologic response to tarp vaccination in prostate cancer patients. Clinical cancer research: an official journal of the American Association for Cancer Research. 2017. 47 Feaver, RE, Cole, BK, Lawson, MJ, Hoang, SA, Marukian, S, Blackman, BR et al. Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis. JCI insight. 2016;1:e90954. 48Vernetti, LA, Senutovitch, N, Boltz, R, DeBiasio, R, Shun, TY, Gough, A et al. A human liver microphysiology platform for investigating physiology, drug safety, and disease models. Experimental biology and medicine. 2016;241: 101-114. 49 Stephenson, D, Hu, MT, Romero, K, Breen, K, Burn, D, Ben-Shlomo, Y et al. Precompetitive data sharing as a catalyst to address unmet needs in Parkinson’s disease. Journal of Parkinson’s disease. 2015;5:581-594. 50 Hart, BA, Jagessar, SA, Kap, YS, Haanstra, KG, Philippens, IH, Serguera, C et al. Improvement of preclinical animal models for autoimmune-mediated disorders via reverse translation of failed therapies. Drug discovery today. 2014;19:1394-1401.


25


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72